Welcome to our dedicated page for Pharma-Bio Serv SEC filings (Ticker: PBSV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pharma-Bio Serv, Inc. (PBSV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Pharma-Bio Serv is described in its public communications as a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm serving pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries.
Among the filings available for PBSV are current reports on Form 8-K. For example, a Form 8-K dated September 15, 2025 states that Pharma-Bio Serv issued a press release announcing its results of operations for the three and nine months ended July 31, 2025, and that the press release is furnished as an exhibit to that report. The filing also notes that the information under that item is furnished rather than filed for purposes of certain provisions of the Securities Exchange Act of 1934 and the Securities Act of 1933.
Through this page, users can monitor Pharma-Bio Serv’s SEC disclosures, including current reports that reference earnings press releases and other material events. Stock Titan enhances these filings with AI-powered summaries that explain the key points of each document in plain language, helping readers understand the significance of the information without having to parse every technical detail.
Filings are updated from the SEC’s EDGAR system, and users can review items such as Form 8-K reports that relate to results of operations and financial condition. The AI tools on this page are designed to highlight important elements within each filing so that investors and researchers can quickly grasp the main disclosures for PBSV.
Pharma-Bio Serv reported revenues of approximately $2.3 million for the quarter ended January 31, 2026, a decrease of about $0.2 million from the same period last year. Despite lower sales, the company posted net income of $32,860, an improvement of $24,324 compared with a slight loss a year earlier.
Management highlighted ongoing efforts to sharpen the service portfolio, reinforce operational alignment, and focus on markets where its consulting capabilities add the most value. The CEO stated that improved operational efficiency supported the return to profit and expressed confidence in building momentum through stronger client relationships and disciplined cost management.
Pharma-Bio Serv, Inc. reported nearly flat operations but remained profitable for the quarter ended January 31, 2026. Revenue was about $2.3 million, down from $2.5 million a year earlier, as U.S. and Europe consulting projects declined while Puerto Rico inched up.
Gross margin was stable at 31.5%, with a small operating loss of $94,535 offset by $131,025 of other income, mainly interest and foreign exchange gains, yielding net income of $32,860. Earnings per share were effectively breakeven at $0.001.
The company ended the quarter with $5.8 million in cash and $4.8 million in marketable U.S. Treasury securities, and working capital of about $10 million. It declared a $0.075 per-share cash dividend (about $1.72 million) and repurchased 3,100 shares at $0.54. Headquarters moved to a virtual model after its only long-term lease expired, and management believes existing resources are sufficient to fund operations beyond the next twelve months.
Pharma-Bio Serv, Inc. filed Amendment No. 1 to its annual report for the year ended October 31, 2025 to add updated Part III information on governance, compensation, ownership and auditor matters. The amendment does not change the previously reported financial results and is meant to be read together with the original Form 10-K.
The filing details a four‑member, fully independent board under Nasdaq standards, with standing audit, compensation, and nominating committees. It describes long‑tenured CEO Victor Sanchez and CFO Pedro Lasanta, whose salaries in fiscal 2025 were $231,000 and $175,000, respectively, with only statutory bonuses and limited perquisites.
Independent directors each received $50,000 in cash fees plus stock options. The company discloses a related‑party AI Agreement: for $250,000 it obtained an AI‑based lead generation platform, a 2.44% interest in an AI company and an option to raise that interest to 16.67%. Crowe PR PSC billed $113,740 in audit and related services for 2025, all pre‑approved by the audit committee.
Pharma-Bio Serv, Inc. reported that it has released its financial results for the year ended October 31, 2025. The company announced these full-year results through a press release dated January 29, 2026, which is attached to this report as Exhibit 99.1.
The filing emphasizes that the press release and related financial information are being furnished rather than filed, meaning they are not automatically incorporated into other securities filings unless specifically referenced.
Pharma-Bio Serv, Inc. reports results for the year ended October 31, 2025, highlighting a small net loss and stronger margins in its global compliance consulting business. Revenue was about $9.0 million, down from $9.5 million, as growth in Europe was offset by softer demand in Puerto Rico, the United States and Brazil.
Gross profit margin improved to 32.3% from 26.5% as project mix and pricing boosted profitability, reducing the net loss to roughly $0.1 million from $0.8 million. Three major customers provided 43.5% of revenue, underscoring client concentration risk. Working capital of about $11.6 million supports operations, dividends and buybacks.
The company paid a $0.075 per share cash dividend and repurchased shares under its ongoing program, while shifting to a fully remote structure except for a small Madrid office. It also holds a $6.7 million judgment against a customer, though collection remains uncertain. Management cites tax changes, Puerto Rico economic conditions, industry consolidation and cybersecurity as key risks.
Pharma-Bio Serv, Inc. reported an insider equity award for Chairman and director Kirk Michel. On January 10, 2026, he received a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share, expiring on January 10, 2031. The option vests in two equal installments on July 10, 2026 and July 10, 2027, meaning half of the option becomes exercisable on each of those dates.
Pharma-Bio Serv, Inc. reported a routine insider equity award for director Dov Perlysky. On January 10, 2026, he was granted a stock option covering 20,000 shares of common stock at an exercise price of
Pharma-Bio Serv, Inc. director Howard Spindel reported a new stock option grant. On January 10, 2026, he was awarded 20,000 stock options with an exercise price of $0.54 per share, each option corresponding to one share of common stock.
The options vest in two equal installments on July 10, 2026 and July 10, 2027, meaning half become exercisable on each of those dates. Following this grant, Spindel beneficially owns 20,000 derivative securities, held directly, according to the report.
Pharma-Bio Serv, Inc. director Irving L. Wiesen reported a new stock option grant on a Form 4. On January 10, 2026, he received a stock option for 20,000 shares of Pharma-Bio Serv common stock. The option has an exercise price of $0.54 per share and an expiration date of January 10, 2031.
According to the filing, the option vests in two equal installments on July 10, 2026 and July 10, 2027. After this grant, Wiesen beneficially owns 20,000 derivative securities related to these options, held in direct ownership.
Pharma-Bio Serv, Inc. filed a current report to disclose that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025. The press release is furnished as Exhibit 99.1 to the report, providing the detailed financial and operating results for that period. The company clarifies that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. The report is signed on behalf of the company by Pedro J. Lasanta, its Chief Financial Officer, Vice President Finance and Administration, and Secretary.